Risk Mitigation in Breast Predictive Factor Testing
In this course, the risks to laboratories and pathologists inherent in biomarker testing are described along with a process to identify and mitigate the risks of testing.
Originally presented on February 10, 2015 in Park City, Utah.
Elizabeth H. Hammond, MD, FCAP
Consulting Pathologist, Intermountain Healthcare
Professor of Pathology, University of Utah School of Medicine
Dr. Elizabeth Hammond is a consulting pathologist with Intermountain Healthcare and professor of pathology and adjunct professor of internal medicine (cardiology) at the University of Utah School of Medicine. She is also a past member of Intermountain’s Board of Trustees. She was recently recognized and presented with two awards presented by the College of American Pathologists (CAP): 1) the CAP Pathology Advancement Award, of which she is the first recipient; and 2) the CAP Excellence in Education Award.
After this presentation, participants will be able to:
- Describe the categories of risks of biomarker testing for laboratories and give examples.
- Define a process of identifying specific laboratory risks of biomarker testing and then defining interventions that will mitigate those risks for the laboratories.
University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories